



fw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Von Seggern, D. (sole inventor) Art Unit : Unknown
Serial No. : 10/808,758 Examiner : Unknown
Cust. No. : 20985
Filed : March 24, 2004
Title : ADENOVIRUS PARTICLES WITH ENHANCED INFECTIVITY OF
DENDRITIC CELLS AND PARTICLES WITH DECREASED INFECTIVITY
OF HEPATOCYTES

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Dear Sir:

Transmitted herewith are an Information Disclosure Statement, Form PTO-1449 (21 pages) and cited non-U.S. document references for filing in connection with the above-identified application. Because this Information Disclosure Statement is filed prior to receipt of a first Office Action on the merits in the above-referenced application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 06-1050, as stated below:



The Commissioner is hereby authorized to charge any fees that may be due in connection with this paper or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

Respectfully submitted,

Stephanie L. Seidman
Reg. No. 33,779

Dated: September 23, 2004
Attorney Docket No. 17083-015001/1239
Address all correspondence to:
Stephanie L. Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-5070
Facsimile: (202) 626-7796
email: seidman@fr.com



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Von Seggern, D. (sole inventor) Art Unit : Unknown
Serial No. : 10/808,758 Examiner : Unknown
Cust. No. : 20985
Filed : March 24, 2004
Title : ADENOVIRUS PARTICLES WITH ENHANCED INFECTIVITY OF
DENDRITIC CELLS AND PARTICLES WITH DECREASED INFECTIVITY
OF HEPATOCYTES

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT IN
ACCORDANCE WITH 37 C.F.R. §§1.97-1.98

Dear Sir:

Since this Information Disclosure Statement is filed before the receipt of a first Office Action on the merits for the above-captioned application, a fee for filing this statement should not be due. If, however, it is determined that a fee is due, any fees that may be due in connection with filing this paper may be charged to Deposit Account No. 06-1050.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §1.97-1.98. Forms PTO-1449 (21 pages) and copies of the cited documents are provided herewith.

The documents listed on Form PTO-1449, are in the English language, with the exception of items AW, BD, BG, BP, BY, CH, FV and MA. Items AW (EP0892047), BD (WO 95/02697), and BY (WO 98/44121), which are in the French language, are provided with English language Derwent abstracts (items EV, ET and EU, respectively). Item CH (WO 00/03028), which is in the German language, is provided with an English language Derwent abstract (item ES). Items

Applicant : Von Seggern (Sole Inventor)
Serial No. : 10/808,758
Filed : March 24, 2004
Information Disclosure Statement
Page : 2 of 3

Attorney's Docket No.: 17083-015001/1239



BG (WO 95/26409) and BP (WO 96/28978), which are in the French language, and item MA (Tatsumi *et al.*), which is in the Japanese language, are provided with Certified English Translations (items EA, EB and DZ, respectively). Item FV (Guo *et al.*), which is in the Chinese language, is provided with an English language abstract on the first page of the publication. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Applicant also makes known to the Examiner the following pending U.S. and International Applications that have one or more common inventors and/or are commonly owned:


<u>U.S.S.N.</u>	<u>Filing Date</u>	<u>Docket No.</u>
09/586,625	06/02/00	17083-003002 (1227B)
10/422,934	04/23/03	17083-003003 (1227C)
09/903,327	07/10/01	17083-004002 (1228B)
10/410,907	04/08/03	17083-005001 (1229)
60/535,199	01/09/04	17083-009P01 (P1233)
09/795,292	01/14/99	17083-011001 (1235)
09/482,682	01/14/00	17083-011002 (1235B)
10/351,890	01/24/03	17083-012001 (1236)
10/403,337	03/27/03	17083-012002 (1236B)

<u>Int'l App. No.</u>	<u>Filing Date</u>	<u>Docket No.</u>
PCT/US03/10856	04/08/03	17083-005WO1 (1229PC)
PCT/US03/02295	01/24/03	17083-012WO1 (1236PC)
PCT/US04/018623	06/10/04	17083-013WO1 (1237PC)

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to

Applicant : Von Seggern (Sole Inventor)
Serial No. : 10/808,758
Filed : March 24, 2004
Information Disclosure Statement
Page : 3 of 3

Attorney's Docket No.: 17083-015001/1239




mean that a search has been made of that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing references and they be made of record in the file history of the above-captioned application.

Respectfully submitted,

Stephanie L. Seidman
Reg. No. 33,779

Dated: September 23, 2004
Attorney Docket No. 17083-015001/1239
Address all correspondence to:
Stephanie L. Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-5070
Facsimile: (202) 626-7796
email: seidman@fr.com



Substitute Form PTO-1449 (Modified) List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17083-015001	Application No. 10/808,758
	Applicant Daniel Von Seggern (Sole Inventor)		
	Filing Date March 24, 2004		Group Art Unit

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	A	2002/0037851	03/28/02	Fleckenstein <i>et al.</i>	514	12	04/16/01
	B	2002/0137213	09/26/02	Hallenbeck <i>et al.</i>	435	456	05/30/01
	C	2002/0168714	11/14/02	Barbas III <i>et al.</i>	435	69.1	07/18/01
	D	2002/0193327	12/19/02	Nemerow	514	44	05/01/01
	E	2003/0157688	08/21/03	Von Seggern <i>et al.</i>	435	235.1	01/14/00
	F	2003/0186841	10/02/03	Barbas <i>et al.</i>	514	1	04/23/03
	G	2003/0215880	11/20/03	Burton <i>et al.</i>	435	7.1	04/08/03
	H	2003/0215948	11/20/03	Kaleko <i>et al.</i>	435	456	03/27/03
	I	2004/0002060	01/01/04	Kaleko <i>et al.</i>	435	5	01/24/03
	J	4328803	05/11/92	Pape	128	276	10/20/80
	K	4356270	10/26/82	Itakura	435	317	11/05/79
	L	4517295	05/14/85	Bracke <i>et al.</i>	435	101	02/18/83
	M	4522811	06/11/85	Eppstein <i>et al.</i>	514	2	07/08/92
	N	5149780	09/22/92	Plow <i>et al.</i>	530	324	10/03/88
	O	5175384	12/29/92	Krimpenfort <i>et al.</i>	800	2	12/05/88
	P	5204445	04/20/93	Plow <i>et al.</i>	530	326	10/02/89
	Q	5229127	07/20/93	McKinzie	424	427	10/03/90
	R	5273056	10/28/93	McLaughlin <i>et al.</i>	128	898	06/12/92
	S	5282851	02/01/94	Jacob-LaBarre	623	6	02/18/92
	T	5292362	03/08/94	Bass <i>et al.</i>	106	124	07/09/91
	U	5543328	08/06/96	McClelland <i>et al.</i>	534	320.1	08/13/93
	V	5559099	09/24/96	Wickham <i>et al.</i>	514	44	09/08/94
	W	5731190	03/24/98	Wickham <i>et al.</i>	435	320.1	09/06/96

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17083-015001	Application No. 10/808,758
	Applicant Daniel Von Seggern (Sole Inventor)		
	Filing Date March 24, 2004	Group Art Unit	

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	X	5750396	05/12/98	Yang <i>et al.</i>	435	357	05/08/95
	Y	5756086	05/26/98	McClelland <i>et al.</i>	424	93.2	02/06/96
	Z	5770442	06/23/98	Wickham <i>et al.</i>	435	20.1	02/21/95
	AA	5789538	08/04/98	Rebar <i>et al.</i>	530	324	04/18/97
	AB	5801029	09/01/98	McCormick	435	172.3	06/07/95
	AC	5871727	02/16/99	Curiel	424	93.2	12/06/96
	AD	5908763	06/01/99	Clark <i>et al.</i>	435	69.5	08/08/94
	AE	5919676	07/06/99	Graham <i>et al.</i>	435	172.3	06/07/95
	AF	5922576	07/13/99	He <i>et al.</i>	435	91.41	02/27/98
	AG	5935935	08/10/99	Connelly <i>et al.</i>	514	44	06/07/95
	AH	5965431	10/12/99	Markl <i>et al.</i>	435	262.5	01/29/98
	AI	5965541	10/12/99	Wickham <i>et al.</i>	514	44	11/28/95
	AJ	5981255	11/09/99	Miyota <i>et al.</i>	435	221	03/25/98
	AK	5994106	11/30/99	Kovesdi <i>et al.</i>	435	91.4	11/26/96
	AL	5994128	11/30/99	Fallaux <i>et al.</i>	435	325	03/25/97
	AM	5998205	12/07/99	Hallenbeck <i>et al.</i>	435	325	07/01/97
	AN	6033908	03/07/00	Bout <i>et al.</i>	435	325	07/15/97
	AO	6057155	05/02/00	Wickham <i>et al.</i>	435	325	08/06/98
	AP	6080569	06/27/00	Graham <i>et al.</i>	435	235.1	09/25/96
	AQ	6140087	10/31/00	Graham <i>et al.</i>	435	91.42	05/31/94
	AR	6156497	12/05/00	Kaleko	435	5	04/13/98
	AS	6281010	08/28/01	Gao <i>et al.</i>	435	325	10/27/95
	AT	6379943	04/30/02	Graham <i>et al.</i>	435	235.1	03/05/99
	AU	6410011	06/25/02	Branellec <i>et al.</i>	424	93.2	06/20/96

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17083-015001	Application No. 10/808,758
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Daniel Von Seggern (Sole Inventor)	
		Filing Date March 24, 2004	Group Art Unit

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AV	2000048	04/03/90	CA				
	AW	0892047	01/20/99	EP				X*
	AX	1054034	03/14/01	EP				
	AY	1054064	11/22/00	EP				
	AZ	1083231	03/14/01	EP				
	BA	9206693	04/30/92	PCT				
	BB	9417832	08/18/94	PCT				
	BC	9500655	01/05/95	PCT				
	BD	9502697	01/26/95	PCT				X*
	BE	9505201	02/23/95	PCT				
	BF	9511984	05/04/95	PCT				
	BG	9526409	10/05/95	PCT			X	
	BH	9526412	10/05/95	PCT				
	BI	9527071	10/12/95	PCT				
	BJ	9534671	12/21/95	PCT				
	BK	9607734	03/14/96	PCT				
	BL	9613276	05/09/96	PCT				
	BM	9614061	05/17/96	PCT				
	BN	9617053	06/06/96	PCT				
	BO	9618418	06/20/96	PCT				
	BP	9622378	07/25/96	PCT			X	
	BQ	9639530	12/12/96	PCT				
	BR	9721826	06/19/97	PCT				
	BS	9737220	10/09/97	PCT				
	BT	9813499	04/02/98	PCT				
	BU	9817783	04/30/98	PCT				

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17083-015001	Application No. 10/808,758
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Daniel Von Seggern (Sole Inventor)	
		Filing Date March 24, 2004	Group Art Unit

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	BV	9822609	05/28/98	PCT				
	BW	9825860	06/18/98	PCT				
	BX	9840508	09/17/98	PCT				
	BY	9844121	10/08/98	PCT				X*
	BZ	9848027	10/29/98	PCT				
	CA	9850053	11/12/98	PCT				
	CB	9854346	12/03/98	PCT				
	CC	9925860	05/27/99	PCT				
	CD	9936545	07/22/99	PCT				
	CE	9938882	08/05/99	PCT				
	CF	9939734	08/12/99	PCT				
	CG	9945132	09/10/99	PCT				
	CH	0003028	01/20/00	PCT				X*
	CI	0003029	01/20/00	PCT				
	CJ	0042208	07/20/00	PCT				
	CK	0073478	12/07/00	PCT				
	CL	0130843	05/03/01	PCT				
	CM	0183729	11/08/01	PCT				
	CN	0192299	12/06/01	PCT				
	CO	0204522	01/17/02	PCT				
	CP	0229072	04/11/02	PCT				
	CQ	02067861	09/06/02	PCT				
	CR	03062400	07/31/03	PCT				
	CS	03085086	10/16/03	PCT				

X*= An English language Derwent abstract is provided.

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17083-015001	Application No. 10/808,758
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Daniel Von Seggern (Sole Inventor)	
		Filing Date March 24, 2004	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig . ID	Document
	CT	Abraham, N.G. <i>et al.</i> , "Adenovirus-mediated heme oxygenase-1 gene transfer into rabbit ocular tissues", <i>Investigative Ophthalmology & Visual Science</i> 36(11): 2202-2210 (1995)
	CU	Akiyama, M. <i>et al.</i> , "In vivo tumor targeting using a tropism-ablated adenovirus targeted to a model receptor," <i>Mol. Ther.</i> 3(5): S168, Abstract No. 471 (May 2001)
	CV	Aleman, R. and D.T. Curiel, "CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors", <i>Gene Ther.</i> 8: 1347-1353 (2001)
	CW	Allison, J. <i>et al.</i> , "Tissue-Specific and Hormonal Regulation of the Gene for Rat Prostatic Steroid-Binding Protein in Transgenic Mice", <i>Mol. Cell. Biol.</i> 9(5): 2254-2257 (1989)
	CX	Amalfitano, A. <i>et al.</i> , "Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors", <i>Proc. Natl. Acad. Sci. USA</i> 93(8): 3352-3356 (1996)
	CY	Arcasoy, S.M. <i>et al.</i> , "Polycations increase the efficiency of adenovirus-mediated gene transfer to epithelial cells in vitro," <i>Gene Ther.</i> 4: 32-38 (1997)
	CZ	Armentano, D. <i>et al.</i> , "Characterization of an Adenovirus Gene Transfer Vector Containing an E4 Deletion", <i>Hum. Gene Ther.</i> 6: 1343-1353 (1995)
	DA	Arnberg, N. <i>et al.</i> , "Fiber Genes of Adenoviruses with Tropism for the Eye and the Genital Tract", <i>Virol.</i> 227: 239-244 (1997)
	DB	Arnberg, N. <i>et al.</i> , "Initial interactions of subgenus D adenoviruses with A549 cellular receptors: sialic acid versus alpha(v) integrins", <i>J. Virol.</i> 74: 42-48 (2000)
	DC	Assil, K.K. <i>et al.</i> , "Multivesicular liposomes. Sustained release of the antimetabolite cytarabine in the eye", <i>Arch Ophthalmol.</i> 105(3): 400-403 (1987)
	DD	ATCC No. CCL-185, A549, "lung; carcinoma"
	DE	ATCC No. CRL-1573, 293, "kidney; transformed with adenovirus 5 DNA"
	DF	ATCC No. CRL-1889, 34, "B lymphocyte; hybridoma"
	DG	Atschul, S.F. <i>et al.</i> , "Basic Local Alignment Search Tool", <i>J. Molec Biol.</i> 215(3): 403-410 (1990)
	DH	Austin, E.A. and Huber, B.E., "A First Step in the Development of Gene Therapy for Colorectal Carcinoma: Cloning, Sequencing, and Expression of <i>Escherichia coli</i> Cytosine Deaminase", <i>Mol. Pharm.</i> 43: 380-387 (1992)
	DI	Bai, M. <i>et al.</i> , "Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells", <i>J. Virol.</i> 67(9): 5198-5205 (1993)
	DJ	Behnam, B. <i>et al.</i> , "Stereotactic Delivery of a Recombinant Adenovirus into a C6 Glioma Cell Line in a Rat Brain Tumor Model: Experimental Study", <i>Neurosurgery</i> 35(5): 910-916 (1994)
	DK	Belousova, N. <i>et al.</i> , "Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein", <i>J. Virol.</i> 76(17): 8621-8631 (2002)

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17083-015001	Application No. 10/808,758
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Daniel Von Seggern (Sole Inventor)	
				Filing Date March 24, 2004	Group Art Unit
Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner Initial	Desig . ID	Document			
	DL	Bergelson, J.M. <i>et al.</i> , "Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5", <i>Science</i> 275(5304): 1320-1323 (1997)			
	DM	Bett, A.J. <i>et al.</i> , "Packaging Capacity and Stability of Human Adenovirus Type 5 Vectors", <i>J. Virol.</i> 67(10): 5911-5921 (1993)			
	DN	Bett, A.J. <i>et al.</i> , "An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3", <i>Proc. Natl. Acad. Sci USA</i> 91(19): 8802-8806 (1994)			
	DO	Bewley, M.C. <i>et al.</i> , "Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR", <i>Science</i> 286(5444): 1579-1583 (1999)			
	DP	Birnboim, H.C. and Doly, J., "A rapid alkaline extraction procedure for screening recombinant plasmid DNA", <i>Nucleic Acids Res.</i> 7(6): 1513-1523 (1979)			
	DQ	Braun, R.E. <i>et al.</i> , "Protamine 3'-untranslated sequences regulate temporal translational control and subcellular localization of growth hormone in spermatids of transgenic mice", <i>Genes & Development</i> 3: 793-802 (1989)			
	DR	Brinster, R.L. <i>et al.</i> , "Expression of a microinjected immunoglobulin gene in the spleen of transgenic mice", <i>Nature</i> 306: 332-336 (1983)			
	DS	Brough, D.E. <i>et al.</i> , "A Gene Transfer Vector-Cell Line System for Complete Functional Complementation of Adenovirus Early Regions E1 and E4", <i>J. Virol.</i> 70(9): 6497-6501 (1996)			
	DT	Brown, E.L. <i>et al.</i> , "Chemical Synthesis and Cloning of a Tyrosine tRNA Gene", <i>Meth. Enzymol.</i> 68: 109-151 (1979)			
	DU	Bucchini, D. <i>et al.</i> , "Pancreatic expression of human insulin gene in transgenic mice", <i>Proc. Natl. Acad. Sci. U.S.A.</i> 83: 2511-2515 (1986)			
	DV	Byk, T. <i>et al.</i> , "Lipofectamine and related cationic lipids strongly improve adenoviral infection efficiency of primitive human hematopoietic cells," <i>Human Gene Ther.</i> 9: 2493-2502 (1998)			
	DW	Cannon, M.J. <i>et al.</i> , "Epstein-Barr Virus Induces Aggressive Lymphoproliferative Disorders of Human B Cell Origin in SCID/hu Chimeric Mice", <i>J. Clin. Invest.</i> 85: 1333-1337 (1990)			
	DX	Carrillo, H. and Lipman, D., "The Multiple Sequence Alignment Problem in Biology", <i>SIAM J. Appl. Math.</i> 48(5): 1073-1082 (1988)			
	DY	Caravokyri, C. and K.N. Leppard, "Constitutive Episomal Expression of Polypeptide IX (pIX) in a 293-Based Cell Line Complements the Deficiency of pIX Mutant Adenovirus Type 5", <i>J. Virol.</i> 69(11): 6627-6633 (1995)			
	DZ	Certified English Translation of Tatsumi <i>et al.</i> , "Thyroid-Stimulating Hormone (Thyrotropin) (TSH) - From Gene Structure to Expression," <i>Nihon Rinsho</i> 47(10): 2213-2220 (1989)			
	EA	Certified English Translation of PCT Application No. WO 95/26409, "Recombinant adenoviruses coding for basic fibroblast growth factors (bFGF)"			
	EB	Certified English Translation of PCT Patent Application No. WO 96/22378, "Cells for the production of recombinant adenoviruses."			

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17083-015001		Application No. 10/808,758	
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Daniel Von Seggern (Sole Inventor)			
				Filing Date March 24, 2004		Group Art Unit	
Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig . ID	Document					
	EC	Cheng Chee-Sheung, C. and Ginsberg, H.S., "Characterization of a Temperature-Sensitive Fiber Mutant of Type 5 Adenovirus and Effect of the Mutation on Virion Assembly", <i>J. Virol.</i> 42(3): 932-950 (1982)					
	ED	Chillon, M. <i>et al.</i> , "Group D adenoviruses infect primary central nervous system cells more efficiently than those from group C", <i>J. Virol.</i> 73(3): 2537-2540					
	EE	Chiu, C.Y. <i>et al.</i> , "Structural analysis of a fiber-pseudotyped adenovirus with ocular tropism suggests differential modes of cell receptor interactions", <i>J. Virol.</i> 75(11): 5375-5380 (2001)					
	EF	Choi, T. <i>et al.</i> , "A Generic Intron Increases Gene Expression in Transgenic Mice", <i>Mol. Cell. Biol.</i> 11(6): 3070-3074 (1991)					
	EG	Chroboczek, J. and Jacrot, B., "The Sequence of Adenovirus Fiber: Similarities and Differences between Serotypes 2 and 5", <i>Virol.</i> 161: 549-554 (1987)					
	EH	Chroboczek, J. <i>et al.</i> , "The Sequence of the Genome of Adenovirus Type 5 and Its Comparison with the Genome of Adenovirus Type 2", <i>Virol.</i> 186: 280-285 (1992)					
	EI	Chroboczek, J. <i>et al.</i> , "Adenovirus Fiber: The molecular repertoire of adenoviruses I," <i>Curr. Top. Microbio. Immunol.</i> 199(Pt.1): 163-200 (1995)					
	EJ	Clark, P.R. <i>et al.</i> , "Polycations and cationic lipids enhance adenovirus transduction and transgene expression in tumor cells," <i>Cancer Gene Ther.</i> 6(5): 437-446 (1999)					
	EK	Craighead, J.E., "Effect of polycations on growth and dissemination of encephalomyocarditis virus in mice," <i>J. Virol.</i> 1(5): 988-995 (1967)					
	EL	Crenshaw III, E.B. <i>et al.</i> , "Cell-specific expression of the prolactin gene in transgenic mice is controlled by synergistic interactions between promoter and enhancer elements", <i>Genes & Development</i> 3: 959-972 (1989)					
	EM	Crystal, R.G. <i>et al.</i> , "Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis", <i>Nature Genetics</i> 8: 42-51 (1994)					
	EN	Danciger, E. <i>et al.</i> , "Olfactory marker protein gene: Its structure and olfactory neuron-specific expression in transgenic mice", <i>Proc. Natl. Acad. Sci. USA</i> 86: 8565-8569 (1989)					
	EO	Dechecci, M.C. <i>et al.</i> , "Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions," <i>Virology</i> 268(2): 382-390 (2000)					
	EP	Dechecci, M.C. <i>et al.</i> , "Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5," <i>J. Virol.</i> 75(18): 8772-8780 (2001)					
	EQ	Defer, C. <i>et al.</i> , "Human adenovirus-host cell interactions: comparative study with members of subgroups B and C", <i>J. Virol.</i> 64(8): 3661-3673 (1990)					
	ER	Degryse, E., "In vivo intermolecular recombination in <i>Escherichia coli</i> : application to plasmid constructions", <i>Gene</i> 170: 45-50 (1996)					
	ES	DERWENT #351, WPI Acc. No. 13010371, for Patent No. WO 00/03028 "Optimized production of adenoviral vectors, useful in gene therapy, by overexpressing the anti-apoptotic cell-cycle regulator p21 in the producer cell"					

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17083-015001		Application No. 10/808,758	
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Daniel Von Seggern (Sole Inventor)			
				Filing Date March 24, 2004		Group Art Unit	
Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig . ID	Document					
	ET	DERWENT #010166087, WPI Acc. No.: 1995-067340/199509 for Patent No. WO 9502697, "New defective recombinant adenovirus for gene therapy - contains inverted terminal repeats, encapsidation sequence and heterologous DNA, also cell lines able to complement the virus defect"					
	EU	DERWENT #012125794, WPI Acc. No.: 1998-542706/199846 for Patent No. WO 9844121 A1, "New adenovirus with mutations in the fibre protein to alter binding selectivity - related nucleic acid and cell lines expressing, or mutant viruses containing, the fibre, particularly useful as selective vectors for gene therapy"					
	EV	DERWENT #012277458, WPI Acc. No.: 1999-083564/199908 for European Patent No. EP 892047 A2, "New semaphorin L proteins - used as immunosuppressants and antiinflammatory agents in organ transplants, inflammation therapy, immunotherapy and gene therapy"					
	EW	Devereux, J. <i>et al.</i> , "A comprehensive set of sequence analysis programs for the VAX", <i>Nucleic Acids Res.</i> 12(1 Pt 1): 387-395 (1984)					
	EX	Dietz, A.B. and Vuk-Pavlovic, S., "High efficiency adenovirus-mediated gene transfer to human dendritic cells", <i>Blood</i> 91(2): 392-398 (1998)					
	EY	Edwards, R.H. <i>et al.</i> , "Directed Expression of NGF to Pancreatic α Cells in Transgenic Mice Leads to Selective Hyperinnervation of the Islets", <i>Cell</i> 58: 161-170 (1989)					
	EZ	Einfeld, D.A. <i>et al.</i> , "Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions", <i>J. Virol.</i> 75(23): 11284-11291 (2001)					
	FA	Engelhardt, J.F. <i>et al.</i> , "Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses", <i>Nature Genetics</i> 4: 27-34 (1993)					
	FB	Falgout, B. and G. Ketner, "Characterization of Adenovirus Particles Made by Deletion Mutants Lacking the Fiber Gene", <i>J. Virol.</i> 62(2): 622-625 (1988)					
	FC	Fallaux, F.J. <i>et al.</i> , "New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses", <i>Human Gene Ther.</i> 9(13): 1909-1917 (1998)					
	FD	Fender, P. <i>et al.</i> , Adenovirus dodecahedron, a new vector for human gene transfer", <i>Nature Biotech.</i> 15: 52-56 (1997)					
	FE	Fisher, K.J. <i>et al.</i> , "Recombinant Adenovirus Deleted of All Viral Genes for Gene Therapy of Cystic Fibrosis", <i>Virol.</i> 217: 11-22 (1996)					
	FF	Forss-Petter, S. <i>et al.</i> , "Neuron-Specific Enolase: Complete Structure of Rat mRNA, Multiple Transcriptional Start Sites, and Evidence Suggesting Post-Transcriptional Control", <i>J. Neuroscience Res.</i> 16: 141-156 (1986)					
	FG	Fu, F. <i>et al.</i> , "Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients", <i>Transplantation</i> 62(5): 659-665 (1996)					

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17083-015001		Application No. 10/808,758	
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Daniel Von Seggern (Sole Inventor)			
				Filing Date March 24, 2004		Group Art Unit	
Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig . ID	Document					
	FH	Gall, J. <i>et al.</i> , "Adenovirus Type 5 and 7 Capsid Chimera: Fiber Replacement Alters Receptor Tropism without Affecting Primary Immune Neutralization Epitopes", <i>J. Virol.</i> 70(4): 2116-2123 (1996)					
	FI	Ganesh, S. <i>et al.</i> , "Adenovirus 35 vectors with fiber chimeras exhibit altered tropism in vivo," <i>Mol. Ther.</i> 7(5): S53, Abstract No. 134 (2003)					
	FJ	Ganesh, S. <i>et al.</i> , "Adenovirus 35 vectors with fiber chimeras exhibit altered tropism in vivo," slides (1-17) from the poster presentation at The Meeting of the American Society of Gene Therapy, Abstract No. 134, presented June 5, 2003					
	FK	Gibson, M. <i>et al.</i> , "Adenovirus Fiber Protein (FP) Functions as a Mitogen and an Adjuvant", <i>Cell. Immunol.</i> 73: 397-403 (1982)					
	FL	Gonzalez R. <i>et al.</i> , "Transduction of bone marrow cells by the AdZ.F(pK7) modified adenovirus demonstrates preferential gene transfer in myeloma cells," <i>Human Gene Ther.</i> 10: 2709-2917 (1999)					
	FM	Gonzalez, R. <i>et al.</i> , "Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein," <i>Gene Ther.</i> 6: 314-320 (1999)					
	FN	Gorziglia, M.I. <i>et al.</i> , "Elimination of both E1 and E2a from Adenovirus Vectors Further Improves Prospects for In Vivo Human Gene Therapy", <i>J. Virol.</i> 70(6): 4173-4178 (1996)					
	FO	Gouras, P. <i>et al.</i> , "Reporter gene expression in cones in transgenic mice carrying bovine rhodopsin promoter/lacZ transgenes", <i>Vis. Neurosci.</i> 6: 1227-1231 (1994)					
	FP	Graham, F.L. <i>et al.</i> , "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5", <i>J. Gen. Virol.</i> 36: 59-72 (1977)					
	FQ	Grant no. DAMD17-01-1-0098: <i>Department of Defense Prostate Cancer Research Program</i> , "Adenoviral Gene Therapy Vectors Targeted to Prostate Cancer", pp. 1-34 (2000)					
	FR	Grant no. DAMD17-01-1-0391: <i>Department of Defense Breast Cancer Research Program</i> , "Dendritic Cell-Targeted Adenoviral Cancer Vaccines", pp. 1-29 (2001)					
	FS	Green, N.M. <i>et al.</i> , "Evidence for a repeating cross- β sheet structure in the adenovirus fibre", <i>EMBO J.</i> 2: 1357-1365 (1983)					
	FT	Gribskov, M. and R.R. Burgess, "Sigma factors from <i>E. coli</i> , <i>B. subtilis</i> , phage SP01, and phage T4 are homologous proteins", <i>Nucleic Acids Res.</i> , 14(16): 6745-6763 (1986)					
	FU	Grosschedl, R. <i>et al.</i> , "Introduction of a ? Immunoglobulin Gene into the Mouse Germ Line: Specific Expression in Lymphoid Cells and Synthesis of Functional Antibody", <i>Cell</i> , 38: 647-658 (1984)					
	FV	Guo, H. <i>et al.</i> , "Apoptosis induced by adenovirus-mediated wild-type p53 expression in human pancreatic cancer cells", <i>Chinese Journal of Pathology</i> 27(3): 194-197 (1998) (English Abstract only)					
	FW	Haecker, S.E. <i>et al.</i> , "In Vivo Expression of Full-Length Human Dystrophin from Adenoviral Vectors Deleted of All Viral Genes", <i>Hum. Gene Ther.</i> 7: 1907-1914 (1996)					
	FX	Hallenbeck, P.L. <i>et al.</i> , "A Novel Tumor-Specific Replication-Restricted Adenoviral Vector for Gene Therapy of Hepatocellular Carcinoma", <i>Hum. Gene Ther.</i> 10: 1721-1733 (1999)					
Examiner Signature				Date Considered			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17083-015001	Application No. 10/808,758
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Daniel Von Seggern (Sole Inventor)	
		Filing Date March 24, 2004	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig . ID	Document
	FY	Hallenbeck, P.L. and S.C. Stevenson, "Targetable gene delivery vectors," in <i>Cancer gene therapy: Past achievements and future challenges</i> , in <i>Cancer Gene Therapy: Past Achievements and Future Challenges</i> , edited by Habib Kluwer, Academic/Plenum Publishers, New York, N.Y., Ch.4: pp. 37-46 (2000)
	FZ	Hardy, S. <i>et al.</i> , "Construction of Adenovirus Vectors through Cre-lox Recombination", <i>J. Virol.</i> 71(3): 1842-1849 (1997)
	FAA	Harrison, S. C., "Principles of Virus Structure", <i>Virology</i> 2nd. ed., edited by B.N. Fields, Raven Press, Ltd., New York, Ch. 3: pp. 37-61 (1990)
	FBB	Havenga, M.J.E. <i>et al.</i> , "Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease", <i>J. Virol.</i> 76(9): 4612-20 (2002)
	GA	Hawiger, D. <i>et al.</i> , "Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo", <i>J. Exp. Med.</i> 194(6): 769-779 (2001)
	GB	Hay, C.M. <i>et al.</i> , "Enhanced gene transfer to rabbit jugular veins by an adenovirus containing a cyclic RGD motif in the HI loop of the fiber knob", <i>J. Vasc. Res.</i> 38: 315-323 (2001)
	GC	He, T.-C. <i>et al.</i> , "A simplified system for generating recombinant adenoviruses", <i>Proc. Natl. Acad. Sci USA</i> 95: 2509-2514 (1998)
	GD	Heideman, D.A.M. <i>et al.</i> , "Selective gene transfer into primary human gastric tumors using epithelial cell adhesion molecule-targeted adenoviral vectors with ablated tropism," <i>Human Gene Ther.</i> 13: 1677-1685 (2002)
	GE	Henry, L.J. <i>et al.</i> , "Characterization of the Knob Domain of the Adenovirus Type 5 Fiber Protein Expressed in <i>Escherichia coli</i> ", <i>J. Virol.</i> 68(8): 5239-5246 (1994)
	GF	Hérissé, J. <i>et al.</i> , "Nucleotide sequence of adenovirus 2 DNA fragment encoding for the carboxylic region of the fiber protein and the entire E4 region", <i>Nucleic Acids Res.</i> 9: 4023-4042 (1981)
	GG	Hileman, R.E. <i>et al.</i> , "Glycosaminoglycan-protein interactions: Definition of consensus sites in glycosaminoglycan binding proteins," <i>BioEssays</i> 20: 156-167 (1998)
	GH	Hodges, D. and Crooke, S.T., "Inhibition of splicing of wild-type and mutated luciferase-adenovirus pre-mRNAs by antisense oligonucleotides", <i>Molec. Pharmacology</i> 48: 905-918 (1995)
	GI	Hong, J.S. <i>et al.</i> , "Characterization of the early region 3 and fiber genes of Ad7", <i>Virology</i> 167(2): 545-553 (1988)
	GJ	Hong, J.S. and J.A. Engler, "The Amino Terminus of the Adenovirus Fiber Protein Encodes the Nuclear Localization Signal", <i>Virol.</i> 185: 758-767 (1991)
	GK	Horton, R.M. <i>et al.</i> , "Gene Splicing by Overlap Extension: Tailor-Made Genes Using the Polymerase Chain Reaction", <i>BioTechniques</i> 8(5): 528-535 (1990)
	GL	Horwitz, M.S., "Adenoviridae and Their Replication", Book: <i>Virology</i> , 2nd ed., Raven Press, Ltd., New York, Ch. 60: pp. 1679-1721 (1990)

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17083-015001	Application No. 10/808,758
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Daniel Von Seggern (Sole Inventor)	
				Filing Date March 24, 2004	Group Art Unit
Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner Initial	Desig ID	Document			
	GM	Horwitz, M.S., "Adenoviruses", in <i>Virology</i> , 2nd ed., Raven Press, Ltd., New York, Ch. 61: pp. 1723-1740 (1990)			
	GN	Huang, S. <i>et al.</i> , "Upregulation of Integrins $\alpha v \beta 3$ and $\alpha v \beta 5$ on Human Monocytes and T Lymphocytes Facilitates Adenovirus-Mediated Gene Delivery", <i>J. Virol.</i> 69(4): 2257-2263 (1995)			
	GO	Huang, S. <i>et al.</i> , "Adenovirus Interaction with Distinct Integrins Mediates Separate Events in Cell Entry and Gene Delivery to Hematopoietic Cells", <i>J. Virol.</i> 70(7): 4502-4508 (1996)			
	GP	Huang, S. <i>et al.</i> , "Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes", <i>Proc. Natl. Acad. Sci. U.S.A.</i> 94: 8156-8161 (1997)			
	GQ	Huang, S. <i>et al.</i> , "A Single Amino Acid in the Adenovirus Type 37 Fiber Confers Binding to Human Conjunctival Cells", <i>J. Virol.</i> , 73(4): 2798-2802 (1999)			
	GR	Inaba, K. <i>et al.</i> , "Isolation of dendritic cells", in <i>Current Protocols in Immunology</i> , John Wiley & Sons, Inc., Philadelphia, pp. 3.7.1 – 3.7.15 (1998)			
	GS	Inoue, N. <i>et al.</i> , "Production of specific antibody and T helper 1-dominant cytokine elicited by dendritic cells genetically modified with an adenovirus vector", <i>Immunol. Lett.</i> 70(2): 77-81 (1999)			
	GT	Jakubczak, J.L. <i>et al.</i> , "Adenovirus Type 5 Viral Particles Pseudotyped with Mutagenized Fiber Proteins Show Diminished Infectivity of Coxsackie B-Adenovirus Receptor-Bearing Cells", <i>J. Virol.</i> 75(6): 2972-2981 (2001)			
	GU	Jonuleit, H. <i>et al.</i> , "Efficient transduction of mature CD83+ dendritic cells using recombinant adenovirus suppressed T cell stimulatory capacity", <i>Gene Therapy</i> 7(3): 249-254 (2000)			
	GV	Jooss, K. <i>et al.</i> , "Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers", <i>J. Virol.</i> 72(5): 4212-4223 (1998)			
	GW	Kaplan, D.H. <i>et al.</i> , "Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice", <i>Proc Natl Acad Sci U S A.</i> 95(13): 7556-61 (1998)			
	GX	Kaufman, R.J., "Identification of the components necessary for adenovirus translational control and their utilization in cDNA expression vectors," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 82: 689-693 (1985)			
	GY	Kay, M.A. <i>et al.</i> , "Recombinant Adenoviral Vectors for Hepatic Gene Therapy", Abstract #S310, <i>Cell Biochem.</i> 17E: 207 (1993)			
	GZ	Kibbe, M.R. <i>et al.</i> , "Optimizing cardiovascular gene therapy," <i>Arch. Surg.</i> 135: 191-197 (2000)			
	HA	Kidd, A.H. <i>et al.</i> , "Fiber sequence heterogeneity in subgroup F adenoviruses", <i>Virology</i> 179(1): 139-50 (1990)			
	HB	Kim, J. <i>et al.</i> , "Targeting adenoviral vectors by using the extracellular domain of the coxsackie-adenovirus receptor: improved potency via trimerization", <i>J. Virol.</i> 76(4): 1892-1903 (2002)			
	HC	Kim, S. <i>et al.</i> , "Preparation of Multivesicular Liposomes", <i>Bioch. Bioph. Acta</i> 728(3): 339-348 (1983)			
Examiner Signature			Date Considered		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17083-015001		Application No. 10/808,758	
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Daniel Von Seggern (Sole Inventor)			
				Filing Date March 24, 2004		Group Art Unit	
Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig . ID	Document					
	HD	Kinloch, R. <i>et al.</i> , "Adenovirus Hexon: Sequence Comparison of Subgroup C Serotypes 2 and 5", <i>J. Biol. Chem.</i> 259(10): 6431-6436 (1984)					
	HE	Kirkman, W. <i>et al.</i> , "Adenovirus gene therapy for benign prostate hyperplasia," <i>Mol. Ther.</i> 1(5): S320, Abstract No. 897 (May 2000)					
	HF	Knowles, M.R. <i>et al.</i> , "A Controlled Study of Adenoviral-Vector-Mediated Gen Transfer in the Nasal Epithelium of Patients with Cystic Fibrosis", <i>New England Journal of Medicine</i> 333(13): 823-831 (1995)					
	HG	Krasnykh, V.N. <i>et al.</i> , "Generation of Recombinant Adenovirus Vectors with Modified Fibers for Altering Viral Tropism", <i>J. Virol.</i> 70(10): 6839-6846 (1996)					
	HH	Krougliak, V. and F.L. Graham, "Development of Cell Lines Capable of Complementing E1, E4, and Protein IX Defective Adenovirus Type 5 Mutants", <i>Hum. Gene Ther.</i> 6(12): 1575-1586 (1995)					
	HI	Kumar-Singh, R. and Farber, D.B., "Encapsidated adenovirus mini-chromosome-mediated delivery of genes to the retina: application to the rescue of photoreceptor degeneration," <i>Human Molecular Genetics</i> 7(12): 1893-1900 (1998)					
	HJ	Lanuti, M. <i>et al.</i> , "Use of protamine to augment adenovirus-mediated cancer gene therapy," <i>Gene Ther.</i> 6(9): 1600-1610 (1999)					
	HK	Law, L.K. and Davidson, B.L., "Adenovirus serotype 30 fiber does not mediate transduction via the coxsackie-adenovirus receptor", <i>J Virol.</i> 76(2): 656-61 (2002)					
	HL	Legrand, V. <i>et al.</i> , "Fiberless Recombinant Adenoviruses: Virus Maturation and Infectivity in the Absence of Fiber", <i>J. Virol.</i> , 73(2): 907-919 (1999)					
	HM	Leissner, P. <i>et al.</i> , "Influence of adenoviral fiber mutations on viral encapsidation, infectivity and <i>in vivo</i> tropism", <i>Gene Ther.</i> 8: 49-57 (2001)					
	HN	Leopold, P.L. <i>et al.</i> , "Altered <i>in vivo</i> distribution in murine liver following intravenous administration of tropism-modified adenovirus gene transfer vectors," <i>Mol. Ther.</i> 3(5): S290, Abstract No. 823 (May 2001)					
	HO	Leopold, P.L. <i>et al.</i> , "Adenovirus-mediated gene transfer to pancreatic islets is dominated by fiber-dependent interactions," <i>Mol. Ther.</i> 3(5): S219, Abstract No. 626 (May 2001)					
	HP	Leppla, S.H. <i>et al.</i> , "Development of an improved vaccine for anthrax", <i>J Clin Invest.</i> 110(2): 141-4 (2002)					
	HQ	Letvin, N.L., "Strategies for an HIV vaccine", <i>J. Clin. Invest.</i> 110(1): 15-20 (2002)					
	HR	Levine, A.J. and Ginsberg, H.S., "Mechanism by Which Fiber Antigen Inhibits Multiplication of Type 5 Adenovirus", <i>J. Virol.</i> 1(4): 747-757 (1967)					
	HS	Li, E. <i>et al.</i> , "Signaling antibodies complexed with adenovirus circumvent CAR and integrin interactions and improve gene delivery", <i>Gene Ther.</i> 7: 1593-1599 (2000)					
	HT	Li, E. <i>et al.</i> , "Integrin alpha(v)beta1 is an adenovirus coreceptor", <i>J. Virol.</i> , 75(11): 5405-5409 (2001)					
	HU	Lieber, A. <i>et al.</i> , "Integrating Adenovirus-Adeno-Associated Virus Hybrid Vectors Devoid of All Viral Genes", <i>J. Virol.</i> 73(11): 9314-9324 (1999)					
Examiner Signature				Date Considered			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17083-015001	Application No. 10/808,758
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Daniel Von Seggern (Sole Inventor)	
		Filing Date March 24, 2004	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig . ID	Document
	HV	Linette, J.P. <i>et al.</i> "In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma", <i>J Immunol.</i> 164(6): 3402-12 (2000)
	HW	Loeb, J.E. <i>et al.</i> , "Enhanced expression of transgenes from Adeno-associated virus vectors with the Woodchuck Hepatitis Virus posttranscriptional regulatory element: implications for gene therapy", <i>Hum. Gene Ther.</i> 10: 2295-2305 (1999)
	HX	Lopez, C. <i>et al.</i> , "Efficient production of biologically active human recombinant proteins in human lymphoblastoid cells from integrative and episomal expression vectors", <i>Gene</i> 148: 285-291 (1994)
	HY	Lyons, R.M., "Multiple approaches to treating systemic disease with oncolytic adenoviruses," slides (1-32) from the presentation at the ASM Gene Therapy Conference, Banff, Alberta, Canada (February 28, 2003)
	HZ	Magram, J. <i>et al.</i> , "Alpha-Globin enhancers target expression of a heterologous gene to erythroid tissues of transgenic mice", <i>Mol. Cell. Biol.</i> 9(10): 4581-4584 (1989)
	IA	Marini, F. <i>et al.</i> , "Biodistribution of 2 modified Ad5 adenovirus vectors (Adv) in mice, the enhanced infection AdpK7, and the fiber deleted Ad5.ΔF: Ablation of both the fiber/CAR and integrin/penton interactions is necessary to block infection," <i>Mol. Ther.</i> 3(5): S171, Abstract No. 482 (May 2001)
	IB	Marshall-Neff, J. <i>et al.</i> , "In vivo retargeting to tumors with systemic delivery using Ad5 adenoviral vectors containing the Ad41 short fiber and a RGD targeting ligands," slides (1-14) from the poster presentation at The 10th Annual Meeting of the ESGT, Antibes, France (October 14, 2002)
	IC	Mathias, P. <i>et al.</i> , "Multiple adenovirus serotypes use αv integrins for infection" <i>J. Virol.</i> 68(10): 6811-6814 (1994)
	ID	McVey, J.H. <i>et al.</i> , "Characterization of the Mouse SPARC/Osteonectin Gene", <i>J. Biol. Chem.</i> 263(23): 11111-11116 (1988)
	IE	Michael, S.I. <i>et al.</i> , "Addition of a short peptide ligand to the adenovirus fiber protein", <i>Gene Ther.</i> 2: 660-668 (1995)
	IF	Miller, P.W. <i>et al.</i> , "Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication", <i>Hum Gene Ther.</i> 11(1): 53-65 (2000)
	IG	Mitani, K. <i>et al.</i> , "Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector", <i>Proc. Natl. Acad. Sci. USA</i> 92: 3854-3858 (1995)
	IH	Mittal, S.K. <i>et al.</i> , "Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter", <i>Virus Research</i> 28: 67-90 (1993)
	II	Mittereder, N. <i>et al.</i> , "Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy", <i>J. Virol.</i> 70(11): 7498-7509 (1996)
	IJ	Morsy, M.A. and C.T. Caskey, "Expanded-capacity adenoviral vectors - the helper-dependent vectors", <i>Mol. Med. Today</i> 5(1): 18-24 (1999)

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17083-015001	Application No. 10/808,758
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Daniel Von Seggern (Sole Inventor)	
		Filing Date March 24, 2004	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig . ID	Document
	IK	Muller, M.J. <i>et al.</i> , "Single-Step Induction of Mammary Adenocarcinoma in Transgenic Mice Bearing the Activated <i>c-neu</i> Oncogene", <i>Cell</i> 54: 105-115 (1988)
	IL	Murphy, B.R. and Collins, P.L., "Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics", <i>J Clin Invest.</i> 110(1): 21-27 (2002)
	IM	Muruve, D. <i>et al.</i> , "Adenovirus vector-induced inflammation: activation of p38-MAPK/MAPK signaling during viral cell entry leads to the expression of the C-X-C chemokine IP-10," <i>Mol. Ther.</i> 3(5): S163, Abstract No. 455 (May 2001)
	IN	Narang, S.A. <i>et al.</i> , "Improved Phosphotriester Method for the Synthesis of Gene Fragments", <i>Meth. Enzymol.</i> , 68: 90-98 (1979)
	IO	Nathans, J. and D.S. Hogness, "Isolation and nucleotide sequence of the gene encoding human rhodopsin", <i>Proc. Natl. Acad. Sci. U.S.A.</i> 81: 4851-4855 (1984)
	IP	NCBI Nucleotide, M12411
	IQ	NCBI Nucleotide, M18369
	IR	NCBI Nucleotide, M73260
	IS	Needleman, S.B. and Wumsch, C.D., "A general method applicable to the search for similarities in the amino acid sequence of two proteins", <i>J. Mol. Biol.</i> 48: 443-453 (1970)
	IT	Nemerow, G.R. and P.L. Stewart "Role of α_v Integrins in Adenovirus Cell Entry and Gene Delivery", <i>Microbiology and Molecular Biology Reviews</i> 63(3): 725-734 (1999)
	IU	Nemerow, G.R., "Adenoviral Vectors - new insights", <i>Trends in Microbiology</i> 8(9): 391-394 (2000)
	IV	Nemerow, G.R., "Cell receptors involved in adenovirus entry", <i>Virology</i> 274: 1-4 (2000)
	IW	Nemerow, G.R. and P.L. Stewart "Antibody neutralization epitopes and integrin binding sites on nonenveloped viruses", <i>Virology</i> 288: 189-191 (2001)
	IX	Neumann, R. <i>et al.</i> , "Determination of the nucleotide sequence for the penton-base gene of human adenovirus type 5", <i>Gene</i> 59: 153-157 (1988)
	JA	Nicklin, S.A. <i>et al.</i> , "Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus", <i>Mol. Ther.</i> 4(6): 534-542 (2001)
	JB	Nicklin, S.A. <i>et al.</i> , "Transductional and transcriptional targeting of cancer cells using genetically engineered viral vectors", <i>Cancer Lett.</i> 201(2): 165-173 (2003)
	JC	Nicklin, S.A. <i>et al.</i> , "In Vitro and in vivo characterization of endothelial cell selective adenoviral vectors", <i>J. Gene Med.</i> 6(3): 300-308 (2004)
	JD	Novelli, A. and P.A. Boulanger, "Assembly of Adenovirus Type 2 Fiber Synthesized in Cell-free Translation System", <i>J. Biol. Chem.</i> 266(14): 9299-9303 (1991)
	JE	Oberholzer, A. <i>et al.</i> "Increased survival in sepsis by in vivo adenovirus-induced expression of IL-10 in dendritic cells", <i>J Immunol.</i> 168(7): 3412-8 (2002)

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17083-015001	Application No. 10/808,758
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Daniel Von Seggern (Sole Inventor)	
		Filing Date March 24, 2004	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig . ID	Document
	JF	Overbeek, P.A. <i>et al.</i> , "Lens-specific expression and developmental regulation of the bacterial chloramphenicol acetyltransferase gene driven by the murine α A-crystallin promoter in transgenic mice", <i>Proc. Natl. Acad. Sci. USA</i> 82: 7815-7819 (1985)
	JG	Palese, P. and A. Garcia-Sastre, "Influenza vaccines: present and future", <i>J Clin Invest.</i> 110(1): 9-13 (2002)
	JH	Palmiter, R.D. and R.L. Brinster "Germ-line Transformation of Mice", <i>Ann. Rev. Genet.</i> 20: 465-499 (1986)
	JI	Parks, R.J. <i>et al.</i> , "A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal", <i>Proc. Natl Acad. Sci. USA</i> 93: 13565-13570 (1996)
	JJ	Pearson, A.S. <i>et al.</i> , "Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines," <i>Clin. Cancer Res.</i> 5: 4208-4213 (1999)
	JK	Pearson, W.R. and Lipman, D.J., "Improved tools for biological sequence comparison", <i>Proc Natl Acad Sci U.S.A.</i> 85(8): 2444-8 (1988)
	JL	Peschon, J.J. <i>et al.</i> , "Expression of Mouse Protamine 1 Genes in Transgenic Mice", <i>Annals New York Academy of Sciences</i> , 564: 186-197 (1989)
	JM	Petitclerc, D. <i>et al.</i> , "The effect of various introns and transcription terminators on the efficiency of expression vectors in various cultured cell lines and in the mammary gland of transgenic mice", <i>J. Biotech.</i> 40: 169-178 (1995)
	JN	Philipson, L. <i>et al.</i> , "Virus-receptor interaction in an adenovirus system", <i>J. Virol.</i> 2(11): 1064-1075 (1968)
	JO	Pisa, P. <i>et al.</i> , "Epstein-Barr Virus Induced Lymphoproliferative Tumors in Severe Combined Immunodeficient Mice Are Oligoclonal", <i>Blood</i> 79(1): 173-179 (1992)
	JP	Plebanski, M. <i>et al.</i> "Immunogenetics and the design of Plasmodium falciparum vaccines for use in malaria-endemic populations", <i>J Clin Invest.</i> 110(3): 295-301 (2002)
	JQ	Qui, C. <i>et al.</i> , "Cationic liposomes enhance adenovirus entry via a pathway independent of the fiber receptor and α -integrins," <i>Human Gene Ther.</i> 9: 507-520 (1998)
	JR	Rabinowitz, J.E. and Samulski, R.J., "The adeno-associated virus crystal: Impact inversely proportional to size," <i>Mol. Ther.</i> 6(4): 443-445 (2002)
	JS	Ranieri, E. <i>et al.</i> , "Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination", <i>J Virol.</i> 73(12): 10416-25 (1999)
	JT	Rea, D. <i>et al.</i> "Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells", <i>J Immunol.</i> 166(8): 5236-5244 (2001)
	JU	Reichel, M.B. <i>et al.</i> , "Immune responses limit adenovirally mediated gene expression in the adult mouse eye", <i>Gene Therapy</i> 5(8): 1038-1046 (1998)

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17083-015001		Application No. 10/808,758	
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Daniel Von Seggern (Sole Inventor)			
				Filing Date March 24, 2004		Group Art Unit	
Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig . ID	Document					
	JV	Ribas <i>et al.</i> , "Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells", <i>Cancer Res.</i> 57(14): 2865-9 (1997)					
	JW	Rich, D.P. <i>et al.</i> , "Development and Analysis of Recombinant Adenoviruses for Gene Therapy of Cystic Fibrosis", <i>Hum. Gene Ther.</i> 4: 461-476 (1993)					
	JX	Roberts, R.J. <i>et al.</i> , "DNA Sequences from the Adenovirus 2 Genome", <i>J. Biol. Chem.</i> 259(22): 13968-13975 (1984)					
	JY	Roelvink, P.W. <i>et al.</i> , "The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F", <i>J Virol.</i> 72(10): 7909-7915 (1998)					
	JZ	Roelvink, P.W. <i>et al.</i> , "Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae", <i>Science</i> 286: 1568-1571 (1999)					
	KA	Roelvink, P.W. <i>et al.</i> , "A prototype retargeted adenovirus vector for human gene therapy," <i>Mol. Ther.</i> 1(5): S27, Abstract No. 30 (May 2000)					
	KB	Roelvink, P.W. <i>et al.</i> , "Genetically targeting adenovirus vectors," Abstract from, 2001 Meeting on Vector Targeting Strategies for Gene Therapy, Cold Spring Harbor, N.Y., p.55 (March 15, 2001)					
	KC	Roelvink, P.W. <i>et al.</i> , "Genetically retargeted adenovirus vectors for human gene therapy," <i>Mol. Ther.</i> 3(5): S169, Abstract No. 473 (May 2001)					
	KD	Rosenfeld, M.A. <i>et al.</i> , "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium", <i>Cell</i> 68: 143-155 (1992)					
	KE	Rowe, M. <i>et al.</i> , "Analysis of Epstein-Barr Virus Gene Expression in Lymphomas Derived from Normal Human B Cells Grafted into SCID Mice", <i>Curr. Topics in Microbiol. Immunol.</i> 166: 325-331 (1990)					
	KF	Ruigrok, R.W.H. <i>et al.</i> , "Structure of adenovirus fiber, II. Morphology of single fibers", <i>J. Mol. Biol.</i> 215: 589-596 (1990)					
	KG	Rusconi, S. and G. Kohler, "Transmission and expression of a specific pair of rearranged immunoglobulin mu and kappa genes in a transgenic mouse line", <i>Nature</i> 314: 330-334 (1985)					
	KH	Sahin, U. <i>et al.</i> , "Human neoplasms elicit multiple specific immune responses in the autologous host", <i>Proc. Natl. Acad. Sci. U.S.A.</i> 92(25): 11810-11813 (1995)					
	KI	Sambrook, E.F., Fritsch, T., Maniatis, in: <i>Molecular Cloning, A Laboratory Manual</i> , Cold Spring Harbor Laboratory Press, vol. 3, p. B.13 (1989)					
	KJ	Sandig, V. <i>et al.</i> , "Optimization for the helper-dependent adenovirus system for production and potency <i>in vivo</i> ", <i>Proc. Natl. Acad. Sci. U.S.A.</i> 97(3): 1002-1007 (2000)					
	KK	Scanlan, M.J. and D.J. Jager, "Challenges to the development of antigen-specific breast cancer vaccines", <i>Breast Cancer Research</i> 3(2): 95-8 (2001)					
	KL	Schwartz and Dayhoff, eds., <i>Atlas of Protein Sequence and Structure</i> , National Biomedical Research Foundation, pp. 353-358 (1979)					
Examiner Signature				Date Considered			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17083-015001		Application No. 10/808,758	
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Daniel Von Seggern (Sole Inventor)			
				Filing Date March 24, 2004		Group Art Unit	
Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig ID	Document					
	KM	Segerman, A. <i>et al.</i> , "Adenovirus types 11p and 35p show high binding efficiencies for committed hematopoietic cell lines and are infective to these cell lines", <i>J. Virol.</i> 74(3): 1457-1467 (2000)					
	KN	Shani, M., "Tissue-Specific and Developmentally Regulated Expression of a Chimeric Actin-Globin Gene in Transgenic Mice", <i>Mol. Cell. Biol.</i> 6(7): 2624-2631 (1986)					
	KO	Shayakhmetov, D.M. <i>et al.</i> , "Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector", <i>J Virol.</i> 74(6): 2567-83 (2000)					
	KP	Shayakhmetov, D.M. <i>et al.</i> , "The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses," <i>J. Virol.</i> , 77(6): 3712-3723 (2003)					
	KQ	Shayakhmetov, D.M. <i>et al.</i> , "Binding of adenovirus fiber knob to blood coagulation factors mediates CAR-independent liver tropism," <i>Mol. Ther.</i> 7(5): S165, Abstract No. 418 (May 2003)					
	KR	Shenk, T., "Adenoviridae: The Viruses and Their Replication", in: <i>Virology</i> 3rd edition, Fields, <i>et al.</i> (eds.), Raven Publishers Philadelphia, Ch. 67: pp.2111-2148 (1996)					
	KS	Shiloh, B.-Z. and R.A. Weinberg, "DNA sequences homologous to vertebrate oncogenes are conserved in <i>Drosophila melanogaster</i> ", <i>Proc Natl Acad Sci U S A.</i> 78(11): 6789-6792 (1981)					
	KT	Signas, C. <i>et al.</i> , "Adenovirus 3 fiber polypeptide gene: implications for the structure of the fiber protein", <i>J Virol.</i> 53(2): 672-678 (1985)					
	KU	Smith <i>et al.</i> , "Comparison of Biosequences", <i>Adv. Appl. Math.</i> 2:482-489 (1981)					
	KV	Smith <i>et al.</i> , "In vivo hepatic adenovirus gene delivery occurs independently of the coxsackie-adenovirus receptor", <i>Mol. Ther.</i> 5(6):770-779 (2002)					
	KW	Smith <i>et al.</i> , "Adenovirus targeting via fiber modification: Mutations to ablate CAR binding combined with insertion of targeting ligands," <i>Mol. Ther.</i> 3(5):S169, Abstract No. 475 (May 2001)					
	KX	Smith <i>et al.</i> , "Adenovirus targeting via fiber modification: Mutations to ablate CAR binding combined with insertion of targeting ligands," slides (9 pages) from the poster presentation at the Annual Meeting of the American Society of Gene Therapy, Abstract No. 475 (June 2001)					
	KY	Smith <i>et al.</i> , "Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice," <i>Human Gene Ther.</i> 14: 777-787 (2003)					
	KZ	Smith <i>et al.</i> , "Detargeting adenoviral vectors from the liver via serotype switching of the fiber protein," <i>Mol. Ther.</i> 5(5), Abstract No. 637 (May 2002)					
	LA	Smith <i>et al.</i> , "Detargeting adenoviral vectors from the liver via serotype switching of the fiber protein," slides (9 pages) from the poster presentation at the Annual Meeting of the American Society of Gene Therapy, Abstract No. 637 (June 2002)					
	LB	Smith <i>et al.</i> , "Heparan sulfate proteoglycans, and not CAR or integrins, are the major receptors for hepatic adenoviral transduction in vivo," <i>Mol. Ther.</i> 5(5):S149, Abstract No. 458 (May 2002)					

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17083-015001	Application No. 10/808,758
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Daniel Von Seggern (Sole Inventor)	
		Filing Date March 24, 2004	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig . ID	Document
	LC	Smith <i>et al.</i> , "Heparan sulfate proteoglycans, and not CAR or integrins, are the major receptors for hepatic adenoviral transduction in vivo," slides (15) from the presentation at the Annual Meeting of the American Society of Gene Therapy (June 7, 2002)
	LD	Smith. T.A.G., "Heparan sulfate proteoglycans, and not CAR or integrins, are the major receptors for hepatic adenoviral transduction in vivo," slides (7 pages) from the poster presentation (Abstract LB-41) at the AACR Meeting, San Francisco, California (April 2002)
	LE	Smith <i>et al.</i> , "In vivo retargeting to tumors using adenoviral vectors containing novel fiber shaft modification," The 10th Annual Meeting of the ESGT, Antibes, France, Abstract No. P61 (October 13, 2002)
	LF	Smith <i>et al.</i> , "In vivo retargeting to tumors using adenoviral vectors containing novel fiber shaft modification," slides (1-14) from the poster presentation at The 10th Annual Meeting of the ESGT, Antibes, France, Abstract No. P61 (October 14, 2002)
	LG	Smith <i>et al.</i> , "Genetic targeting of adenoviral vectors for systemic administration," <i>Mol. Ther.</i> 7(5):S53, Abstract No. 135 (May 2003)
	LH	Smith <i>et al.</i> , "Genetic targeting of adenoviral vectors for systemic administration," slides (1-13) from the poster presentation at the Annual Meeting of the American Society of Gene Therapy, Abstract No. 135 (June 5, 2003)
	LI	Smith <i>et al.</i> , "Interactions involved in adenoviral-mediated gene delivery in nonhuman primates following systemic delivery," slides (9 pages) from the poster presentation at the ASM Gene Therapy Conference, Banff, Canada (February 27, 2003)
	LJ	Sonderbye, L. <i>et al.</i> "In vivo and in vitro modulation of immune stimulatory capacity of primary dendritic cells by adenovirus-mediated gene transduction", <i>Experimental and Clinical Immunogenetics</i> , 15(2): 100-111 (1998)
	LK	Sorscher, E.J. <i>et al.</i> , "Tumor cell bystander killing in colonic carcinoma utilizing the <i>Escherichia coli</i> DeoD gene to generate toxic purines", <i>Gene Ther.</i> 1: 233-238 (1994)
	LL	Spector, D. J., "The Pattern of Integration of Viral DNA Sequences in the Adenovirus 5-Transformed Human Cell Line 293", <i>Virology</i> 130: 533-538 (1983)
	LM	Steinbrink, K. <i>et al.</i> , "Induction of tolerance by IL-10-treated dendritic cells", <i>J Immunol.</i> 159(10): 4772-4780 (1997)
	LN	Steinman, R.M. and Pope, M., "Exploiting dendritic cells to improve vaccine efficacy", <i>J Clin Invest.</i> 109(12): 1519-1526 (2002)
	LO	Steinman, R.M. <i>et al.</i> , "Tolerogenic dendritic cells", <i>Annu Rev Immunol.</i> 21: 685-711 (2003)
	LP	Steinman, R.M. <i>et al.</i> , "The induction of tolerance by dendritic cells that have captured apoptotic cells", <i>J. Exp. Med.</i> 191(3): 411-416 (2000)
	LQ	Stevenson, S.C. <i>et al.</i> , "Human Adenovirus Serotypes 3 and 5 Bind to Two Different Cellular Receptors via the Fiber Head Domain", <i>J. Virol.</i> 69(5): 2850-2857 (1995)
	LR	Stevenson, S.C. <i>et al.</i> , "Selective Targeting of Human Cells by a Chimeric Adenovirus Vector Containing a Modified Fiber Protein", <i>J. Virol.</i> 71(6): 4782-4790 (1997)

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17083-015001	Application No. 10/808,758
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Daniel Von Seggern (Sole Inventor)	
		Filing Date March 24, 2004	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig . ID	Document
	LS	Stevenson, S.C., "Genetic targeting of adenoviral vectors for systemic administration," slides 1-22 from the presentation at the 2001 Meeting on Vector Targeting Strategies for Gene Therapy, Cold Spring Harbor, N.Y. (March 22, 2003)
	LT	Stevenson, S.C., "Strategies for the development of targeted adenoviral vectors," slides (1-16) from the presentation at The 6th Annual Meeting of the American Society of Gene Therapy, Washington, D.C. (June 4, 2003)
	LU	Storb, U. <i>et al.</i> , "High expression of cloned immunoglobulin ϵ gene in transgenic mice is restricted to B lymphocytes", <i>Nature</i> 310: 238-241 (1984)
	LV	Su, E.J. <i>et al.</i> , "A genetically modified adenoviral vector exhibits enhanced gene transfer of human smooth muscle cells", <i>J. Vasc. Res.</i> 38: 471-478 (2001)
	LW	Suhadolnik, R.J. <i>et al.</i> , "Nucleoside Antibiotics: I. Biochemical Tools for Studying the Structural Requirements for Interaction at the Catalytic and Regulatory Sites of Ribonucleotide Reductase from <i>Lactobacillus Leichmannii</i> ", <i>J. Biol. Chem.</i> 243(12): 3532-3537 (1968)
	LX	Summerford, C. and R.J. Samulski, "Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 3 virions," <i>J. Virol.</i> 72(2): 1438-1445 (1998)
	LY	Sutcliffe, J. G., "The genes for myelin", <i>Trends in Genetics</i> 3: 73-76 (1987)
	LZ	Swift, G.H. <i>et al.</i> , "Tissue-Specific Expression of the Rat Pancreatic Elastase I Gene in Transgenic Mice", <i>Cell</i> 38: 639-646 (1984)
	MA	Tatsumi <i>et al.</i> , "Thyroid-Stimulating Hormone (Thyrotropin) (TSH)-From Gene Structure to Expression", <i>Nippon Rinsho</i> 47(10): 2213-2220 (1989)
	MB	Thiel, J.F. and K.O. Smith, "Fluorescent Focus Assay of Viruses on Cell Monolayers in Plastic Petri Plates", <i>Proc. Soc. Exp. Biol. Med.</i> 125: 892-895 (1967)
	MC	Third Annual Meeting, June 2000, of the American Society for Gene Therapy. Publishers web site release 5/3/00 12 noon.
	MD	Thomas, C. <i>et al.</i> , "Altering adenovirus tropism changes cell types transduced, but does not improve acute adenovirus-mediated inflammation," <i>Mol. Ther.</i> 3(5): S162, Abstract No. 452 (May 2001)
	ME	Tillman, B.W. <i>et al.</i> , "Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector", <i>J Immunol.</i> 162(11): 6378-6383 (1999)
	MF	Tomko, R.P. <i>et al.</i> , "HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses", <i>Proc Natl Acad Sci U S A.</i> 94(7): 3352-3356 (1997)
	MG	Townes, T.M. <i>et al.</i> , "Expression of Human α -Globin Genes in Transgenic Mice: Effects of a Flanking Metallothionein-Human Growth Hormone Fusion Gene", <i>Mol. Cell. Biol.</i> 5(8): 1977-1983 (1985)
	MH	Toyoshima, K. and P.K. Vogt, "Enhancement and inhibition of avian sarcoma viruses by polycations and polyanions," <i>Virology</i> 38: 414-426 (1969)

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17083-015001	Application No. 10/808,758
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Daniel Von Seggern (Sole Inventor)	
		Filing Date March 24, 2004	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Design ID	Document
	MI	Tremblay, Y. <i>et al.</i> , "Pituitary-specific expression and glucocorticoid regulation of a proopiomelanocortin fusion gene in transgenic mice", <i>Biochemistry</i> 85: 8890-8894 (1988)
	MJ	Tsubota, K. <i>et al.</i> , "Adenovirus-mediated gene transfer to the ocular surface epithelium", <i>Exp. Eye Res.</i> 67: 531-538 (1998)
	MK	van Beusechem, V.W. <i>et al.</i> , "Targeted adenovirus vectors with high selectivity for human tumors," <i>Mol. Ther.</i> , 3(5): S289 Abstract No. 820 (May 2001)
	ML	van der Bruggen, P. <i>et al.</i> , "A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma", <i>Science</i> 254(5038): 1643-1647 (1991)
	MM	van der Vliet, P.C. <i>et al.</i> , "Thermolabile DNA Binding Proteins from Cells Infected with a Temperature-Sensitive Mutant of Adenovirus Defective in Viral DNA Synthesis", <i>J. Virol.</i> 15(2): 348-354 (1975)
	MN	van Raaij, M.S. <i>et al.</i> , "A triple beta-spiral in the adenovirus fibre shaft reveals a new structural motif for a fibrous protein", <i>Nature</i> 401(6756): 935-938 (1999)
	MO	Vassar, R. <i>et al.</i> , "Tissue-specific and differentiation-specific expression of a human K14 keratin gene in transgenic mice", <i>Proc. Natl. Acad. Sci. U.S.A.</i> 86: 1563-1567 (1989)
	MP	Von Seggern, D.J. <i>et al.</i> , "Complementation of a fibre mutant adenovirus by packaging cell lines stably expressing the adenovirus type 5 fibre protein", <i>J. Gen. Virol.</i> 79: 1461-1468 (1998)
	MQ	Von Seggern D.J. <i>et al.</i> , "An adenoviral gene therapy vector deleted for E1, E3, and fiber: Structure and infectivity of fiberless particles", Conference Abstract, <i>Cancer Gene Ther.</i> 5(6): S14 Abstract No. P-39D (1998)
	MR	Von Seggern, D.J. <i>et al.</i> , "A Helper-Independent Adenovirus Vector with E1, E3, and Fiber Deleted: Structure and Infectivity of Fiberless Particles", <i>J. Virol.</i> 73(2): 1601-1608 (1999)
	MS	Von Seggern, D.J. <i>et al.</i> , "Adenovirus Vector Pseudotyping in Fiber-Expressing Cell Lines: Improved Transduction of Epstein-Barr Virus-Transformed B Cells", <i>J. Virol.</i> 74: 354-362 (2000)
	MT	Von Seggern, D.J. <i>et al.</i> , "Efficient <i>in vivo</i> Transduction of Mouse Photoreceptors by Intravitreal Injection of a Pseudotyped Adenovirus Vector", abstract for <i>The Third Annual Meeting of the American Society of Gene Therapy</i> , Denver, Colorado, May 31 - June 4, 2000 (released on web network May 3, 2000)
	MU	Von Seggern, D.J. <i>et al.</i> , "In vivo transduction of photoreceptors or ciliary body by intravitreal injection of pseudotyped adenoviral vectors", <i>Mol. Ther.</i> 7(1): 27-34 (2003)
	MV	Wallis, C. and J.L. Melnick, "Mechanism of enhancement of virus plaques by cationic polymers," <i>J. Virol.</i> 2(4): 267-274 (1968)
	MW	Wan <i>et al.</i> , "Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination", <i>Hum Gene Ther.</i> Jul 20;8(11):1355-63 (1997)
	MX	Whitley, R.J. and B. Roizman, "Herpes simplex viruses: is a vaccine tenable?", <i>J Clin Invest.</i> 110(2): 145-151 (2002)

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17083-015001	Application No. 10/808,758
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Daniel Von Seggern (Sole Inventor)	
				Filing Date March 24, 2004	Group Art Unit
Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner Initial	Desig . ID	Document			
	MY	Wickham, T.J. <i>et al.</i> , "Integrins $\alpha v \beta 3$ and $\alpha v \beta 5$ Promote Adenovirus Internalization but Not Virus Attachment", <i>Cell</i> 73: 309-319 (1993)			
	MZ	Wickham, T.J. <i>et al.</i> , "Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types," <i>Nature Biotech.</i> 14: 1570-1573 (1996)			
	NA	Wickham, T.J. <i>et al.</i> , "Targeted Adenovirus Gene Transfer to Endothelial and Smooth Muscle Cells by Using Bispecific Antibodies", <i>J. Virol.</i> 70(10): 6831-6838 (1996)			
	NB	Wickham, T.J. <i>et al.</i> , "Increased In Vitro and In Vivo Gene Transfer by Adenovirus Vectors Containing Chimeric Fiber Proteins", <i>J. Virol.</i> 71(11): 8221-8229 (1997)			
	NC	Wickham, T.J. <i>et al.</i> , "Genetically targeting adenovirus vectors," <i>Mol. Ther.</i> 1(5): S11, Abstract No. 2029 (May 2000)			
	ND	Work, L.M. <i>et al.</i> , "Development of efficient viral vectors selective for vascular smooth muscle cells", <i>Mol. Ther.</i> 9(2): 198-208 (2004)			
	NE	Wu, E. <i>et al.</i> , "Characterization of a 50kDa Receptor for Adenoviruses Associated with Severe Ocular Infections", abstract presented at the <i>Keystone Symposium on Cell Biology of Virus Entry, Replication, and Pathogenesis</i> , on March 1, (2000).			
	NF	Wu, E. <i>et al.</i> , "A 50-kDa membrane protein mediates sialic acid-independent binding and infection of conjunctival cells by adenovirus type 37", <i>Virology</i> 279: 78-89 (2001)			
	NG	Wu, E. <i>et al.</i> , "Flexibility of the adenovirus fiber is required for efficient receptor interactions," <i>J. Virol.</i> 77(13): 7225-7235 (2003)			
	NH	Wu, E. <i>et al.</i> , "Membrane cofactor protein is a receptor for adenoviruses associated with epidemic keratoconjunctivitis", <i>J. Virol.</i> 78(8): 3897-905 (2004)			
	NI	Yang, Y. <i>et al.</i> , "Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 91: 4407-4411 (1994)			
	NJ	Yu, Z. and N.P. Restifo, "Cancer vaccines: progress reveals new complexities", <i>J Clin Invest.</i> 110(3): 289-294 (2002)			
	NK	Zabner, J. <i>et al.</i> , "Adenovirus-Mediated Gene Transfer Transiently Corrects the Chloride Transport Defect in Nasal Epithelia of Patients with Cystic Fibrosis", <i>Cell</i> 75:207-216 (1993)			
	NL	Zhang, Y. <i>et al.</i> , "Acute Cytokine Response to Systemic Adenoviral Vectors in Mice Is Mediated by Dendritic Cells and Macrophages", <i>Mol. Ther.</i> 3(5): 697-707 (2001)			
	NM	Zufferey, R. <i>et al.</i> , "Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances Expression of Transgenes Delivered by Retroviral Vectors", <i>J. Virol.</i> 73(4): 2886-2892 (1999)			

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	